EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas

Xiaoyan Li, Xin Wang

Annals of Hematology · 2025-03 · 104 (3) · 1427-1442

DOI: 10.1007/s00277-024-06079-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, online erschienen am 16.11.2024. Verfasst von Xiaoyan Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Lymphoma, B-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Indolent B-cell non-Hodgkin lymphomas(B-NHL) encompass a heterogeneous category of lymphomas characterized by a wide range of pathological subtypes. With the application of chemoimmunotherapy with rituximab (R-chemo), the prognosis of patients has improved considerably, with a 10-year survival rate of 60-80%. Despite these advancements, a significant number of patients still experience disease progression during or shortly after initial treatment. Those who progress within the first 24 months (POD24) continue to face a notably worse prognosis. This study aims to explore the significance of POD24 in predicting the prognosis of different subtypes of indolent B-cell NHL through a comprehensive literature review. The investigation extends to examining the existing prognostic assessment tools and evaluating the interrelationship between POD24 and these tools. By synthesizing relevant research findings, this study seeks to contribute to the current understanding of the role POD24 plays in prognostic evaluation and its potential implications in guiding clinical decision-making for patients with indolent B-cell NHL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, FollicularLymphoma, B-CellHumansPrognosisRituximabDisease ProgressionTime Factors

Stichwörter der Autor:innen

Chronic lymphocytic leukemia/small lymphocytic lymphomaDisease progressionFollicular lymphomaMarginal zone lymphomaPrognostic modelRisk factorslymphoplasmacytic lymphoma/ Waldenström macroglobulinemia

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. xinw@hospital.cqmu.edu.cn.

Förderung

  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Li, X., & Wang, X. (2025). Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas. Annals of Hematology, 104(3), 1427-1442. https://doi.org/10.1007/s00277-024-06079-y

Vancouver

Li X, Wang X. Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas. Annals of Hematology. 2025;104(3):1427-1442. doi:10.1007/s00277-024-06079-y

BibTeX
@article{Li2025,
  author = {Li, Xiaoyan and Wang, Xin},
  title = {Effect of POD24 on the prognosis of follicular and other indolent B-cell non-hodgkin lymphomas},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {3},
  pages = {1427--1442},
  doi = {10.1007/s00277-024-06079-y}
}
Kostenlos starten →